Shares of C R Bard Inc (NYSE:BCR) have been assigned an average recommendation of “Hold” from the eleven analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $332.00.
Several brokerages have issued reports on BCR. ValuEngine downgraded shares of C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective for the company in a research report on Tuesday, December 26th.
The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. The stock has a market capitalization of $24,140.00, a PE ratio of 43.64, a P/E/G ratio of 2.53 and a beta of 0.52. C R Bard has a fifty-two week low of $223.02 and a fifty-two week high of $337.73.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alpine Associates Management Inc. raised its position in shares of C R Bard by 10.0% in the third quarter. Alpine Associates Management Inc. now owns 924,263 shares of the medical instruments supplier’s stock valued at $296,226,000 after buying an additional 83,851 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of C R Bard by 32.8% in the third quarter. Wells Fargo & Company MN now owns 775,683 shares of the medical instruments supplier’s stock valued at $248,607,000 after buying an additional 191,443 shares in the last quarter. Westchester Capital Management LLC increased its stake in C R Bard by 14.6% in the third quarter. Westchester Capital Management LLC now owns 575,106 shares of the medical instruments supplier’s stock valued at $184,321,000 after acquiring an additional 73,478 shares during the last quarter. Cowen Inc. increased its stake in C R Bard by 100.7% in the third quarter. Cowen Inc. now owns 571,487 shares of the medical instruments supplier’s stock valued at $183,162,000 after acquiring an additional 286,685 shares during the last quarter. Finally, Magnetar Financial LLC increased its stake in C R Bard by 11.6% in the third quarter. Magnetar Financial LLC now owns 543,407 shares of the medical instruments supplier’s stock valued at $174,162,000 after acquiring an additional 56,328 shares during the last quarter. Institutional investors own 79.11% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “C R Bard Inc (BCR) Receives $332.00 Consensus Target Price from Analysts” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3257976/c-r-bard-inc-bcr-receives-332-00-consensus-target-price-from-analysts.html.
About C R Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.